Hypoxia-inducible factor-1α suppression in ovarian clear-cell carcinoma cells by silibinin administration

8Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Background/Aim: Advanced ovarian clear-cell carcinoma (CCC) fails to respond to standard chemotherapy, and has a poor prognosis. Since hypoxia-inducible factor-1 (HIF-1) stimulates various genes involved in cancer, we aimed to examine the efficacy of silibinin, an active component of milk thistle belonging to Asteraceae, in suppressing HIF-1 activity, and elucidate the underlying mechanism in human CCC cell lines. Materials and Methods: Human ovarian CCC cell lines HAC-2, OVISE, and RMG-1 were treated with 500 μM silibinin for 4 h under normoxic and hypoxic conditions. Using DNA microarray, we analysed genes whose expression modulated more than 2-fold in response to hypoxia, whereas HIF-1α expression was measured using ELISA. Results: Silibinin treatment decreased HIF-1α protein in all cell lines, and eIF4E2 and RPS6 mRNA in HAC-2 and RMG-1 cells. Conclusion: Silibinin suppressed HIF-1α protein under hypoxic conditions in CCC cell lines and could be a potential anti-cancer drug.

Cite

CITATION STYLE

APA

Miyazawa, M., Yasuda, M., Miyazawa, M., Ogane, N., Katoh, T., Yano, M., … Ishimoto, H. (2020). Hypoxia-inducible factor-1α suppression in ovarian clear-cell carcinoma cells by silibinin administration. Anticancer Research, 40(12), 6791–6798. https://doi.org/10.21873/anticanres.14702

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free